X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.
Lead Product(s): Tretinoin,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Twyneo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: SEARCHLIGHT PHARMA INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
Through a licensing agreement, Apotex will market and distribute Verkazia (cyclosporine) ophthalmic emulsion, which is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.
Lead Product(s): Cyclosporine
Therapeutic Area: Ophthalmology Product Name: Verkazia
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Harrow
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 15, 2024
Details:
Teriparatide Injection, a single-patient-use pre-filled pen and a parathyroid hormone analog, is used for the treatment of osteoporosis in the United States.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Teriparatide-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Ambio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Bendamustine hydrochloride is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring, which can lead to cell death via several pathways. It is active against both quiescent and dividing cells.
Lead Product(s): Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2023
Details:
Apotex Inc. is recalling certain lots of Apo-Acyclovir (acyclovir) tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity (N-nitrosodimethylamine [NDMA]) above the acceptable level.
Lead Product(s): Aciclovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Apo-Acyclovir
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
Paclitaxel is a intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancer.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Abraxane-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Company launched Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution which is a generic version of Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Lead Product(s): Brimonidine Tartrate,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Under the terms of the settlement agreement, Apotex may not sell a generic version of Movantik in the U.S. until October 1, 2030 (subject to U.S. FDA approval) or earlier under certain circumstances.
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Movantik
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 22, 2021
Details:
The three medicines include cefazolin, cefepime and ceftriaxone for injection and are part of the cephalosporin category of antibiotics. Cephalosporins are one of the most widely prescribed classes of medications in the world and treat a variety of bacterial infections.
Lead Product(s): Cefazolin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ProvideGx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 08, 2021
Details:
Chiesi Group expands distribution network via acquisition for worldwide product rights.
Lead Product(s): Deferiprone
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CHIESI USA INC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
